Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dc9d75bedf51340bf01bbaa4d612d989 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_52f2e6de1c6f5a3ba7b48c7196e249b4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_306931c55ec7705464a764aab05a1032 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_191663f2561f98d0ba67c91203359033 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-385 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-57 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-21038 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-727 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-21008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-21027 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-16 |
filingDate |
2012-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_05c0c460a9ae21a0eaae9e68fbb976e0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fbd35a68690ff437d5b9362bce9b717a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90ad41f2a7e30b07892b239fc52cb434 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e4696b605e4067525db5672f019d6174 |
publicationDate |
2014-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2014161899-A1 |
titleOfInvention |
Methods to reduce adverse events caused by pharmaceutical preparations comprising plasma derived proteins |
abstract |
The instant invention provides a method to reduce adverse events caused by a pharmaceutical preparation derived from a plasma fraction wherein the method comprises contacting the plasma fraction with heparin or a heparin-like substance thereby reducing the activity of at least one activated serine proteaseper ml of the plasma fraction. |
priorityDate |
2011-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |